Last updated: January 26, 2026
Summary
JARDIANCE (empagliflozin), developed by Boehringer Ingelheim and Eli Lilly, is a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor approved primarily for managing type 2 diabetes (T2D), heart failure, and chronic kidney disease (CKD). As of 2023, JARDIANCE commands a significant market share within the SGLT2 inhibitor class, driven by its demonstrated cardiovascular and renal benefits. This analysis reviews the latest clinical trial data, assesses current market positioning, and projects future growth trajectories amid evolving therapeutic landscapes and regulatory dynamics.
1. Clinical Trials Update for JARDIANCE
1.1. Recent and Ongoing Clinical Trials
| Trial Name |
Phase |
Indication |
Key Objectives |
Status |
Highlights |
| EMPEROR-Reduced |
Phase 3 |
Heart Failure with Reduced Ejection Fraction (HFrEF) |
Assess CV death, HF hospitalization, renal outcomes |
Completed (Published 2020) |
Empagliflozin significantly reduced the risk of CV death or HF hospitalization (HR 0.75, p<0.001)¹ |
| EMPEROR-Preserved |
Phase 3 |
Heart Failure with Preserved Ejection Fraction (HFpEF) |
Heart failure events and renal outcomes |
Completed (Published 2021) |
Demonstrated reduction in composite CV and renal outcomes in HFpEF² |
| EMPA-KIDNEY |
Phase 3 |
CKD with or without T2D |
Renal composite outcomes |
Ongoing (Expected completion 2024) |
Aims to expand indication to broader CKD populations³ |
| EMPAA-DM |
Phase 4 |
T2D with atherosclerotic cardiovascular disease (ASCVD) |
Long-term safety and efficacy |
Ongoing |
Monitoring cardiovascular and renal benefits in diverse populations |
1.2. Key Clinical Findings
- Cardiovascular Benefits: The EMPEROR studies solidified empagliflozin’s role in reducing CV mortality and HF hospitalizations, expanding its indication beyond glycemic control.
- Renal Outcomes: Both EMPEROR-Reduced and EMPEROR-Preserved show consistent renal protective effects, including slowing eGFR decline and reducing progression to end-stage renal disease (ESRD).
- Safety Profile: Generally well tolerated; common adverse events include genitourinary infections, hypotension, and rare ketoacidosis. No major safety concerns have emerged, reinforcing its profile as a safe cardiovascular and renal agent.
2. Market Analysis of JARDIANCE
2.1. Current Market Size and Share
| Parameter |
Value / Data |
Source |
| Global SGLT2 inhibitor market (2022) |
~$11.2 billion |
Fortune Business Insights[4] |
| JARDIANCE’s share in SGLT2 class |
~30% (2022) |
IQVIA Data[5] |
| Estimated global sales (2022) |
~$4 billion |
Company Reports[6] |
| Market penetration (T2D segment) |
~15 million patients in US (2022) |
CDC Data[7] |
| Market penetration (HFrEF/CKD indications) |
Growing; ≈5 million patients |
Industry estimates[8] |
2.2. Competitive Landscape
| Drug |
Manufacturer |
Indications |
Market Share (2022) |
Key Differentiator |
| JARDIANCE |
Boehringer Ingelheim / Eli Lilly |
T2D, HFrEF, CKD |
~30% |
First to secure CV and renal benefits, approved for multiple indications |
| Invokana (canagliflozin) |
Janssen |
T2D, CKD |
~25% |
First approved SGLT2 inhibitor, higher risk profile for amputations |
| Farxiga (dapagliflozin) |
AstraZeneca |
T2D, HFpEF |
~35% |
Broad indication profile, including HFpEF approval |
| Steglatro (ertugliflozin) |
Pfizer |
T2D |
~10% |
Focused niche targeting |
2.3. Market Drivers & Challenges
| Driver |
Impact |
| Expanding indications (HF, CKD) |
Significantly increasing sales potential |
| Guideline endorsements |
American Diabetes Association (ADA) 2023 now recommends SGLT2 inhibitors for CV and CKD risk reduction |
| Broadened insurance coverage |
Enhances accessibility globally |
| Competition with other SGLT2 inhibitors |
Market share gains require ongoing evidence generation |
| Challenge |
Impact |
| Patent expiry risks (expected 2028) |
Potential price reductions and generics entry |
| Safety concerns (rare ketoacidosis) |
May influence prescribing behaviors |
| Market saturation in T2D |
Need for strong positioning via expanding indications |
3. Market Projection and Future Trends
3.1. Revenue Forecasts (2023-2030)
| Year |
Predicted Global Sales ($ billion) |
CAGR |
Key Assumptions |
| 2023 |
4.2 |
— |
Post-pandemic recovery, ongoing clinical trials supporting broader indications |
| 2024 |
5.0 |
~19% |
Regulatory approvals (HFpEF, CKD), increased awareness |
| 2025 |
6.2 |
~24% |
Market penetration expansion, emergent biosimilar competition |
| 2026 |
7.8 |
~26% |
Pivotal trial data consolidates position; new indication approvals |
| 2027 |
9.0 |
~15% |
Patent expiry approaches; biosimilar impact |
| 2030 |
12.0 |
~20% |
Broadened global use, potential new indications |
3.2. Geographical Market Dynamics
| Region |
2022 Revenue ($ billion) |
Growth Drivers |
Challenges |
| North America |
2.8 |
Robust clinical evidence, guideline adoption |
Price sensitivity, reimbursement constraints |
| EU |
0.9 |
Healthcare access expansion |
Regulatory delays |
| Asia-Pacific |
0.4 |
Growing diabetes prevalence, increasing awareness |
Cost barriers |
| Rest of World |
0.1 |
Limited access, emerging markets |
Infrastructure gaps |
3.3. Key Trends Shaping Future Adoption
- Regulatory Approvals in New Indications: EMA and FDA are reviewing EMPA-KIDNEY and other trials for expanded use in CKD and HFpEF, with potential approval in 2024-2025.
- Combination Therapy Strategies: Increasing concurrent use with other cardiometabolic agents enhances outcomes.
- Real-World Evidence (RWE): Growing datasets support safety and efficacy profiles, easing prescriber concerns.
4. Comparative Analysis with SGLT2 Inhibitors
| Parameter |
JARDIANCE (empagliflozin) |
Farxiga (dapagliflozin) |
Invokana (canagliflozin) |
Ertugliflozin (Steglatro) |
| First Approval |
August 2014 |
May 2014 |
March 2013 |
December 2018 |
| Indications |
T2D, HF, CKD |
T2D, HFpEF, CKD |
T2D, CKD |
T2D |
| CV Benefit Evidence |
Solid (EMPEROR series) |
Strong (DECLARE-TIMI 58, DAPA-HF) |
Moderate |
Limited |
| Renal Benefit Evidence |
Strong |
Moderate |
Limited |
Limited |
| Patent Expiry |
~2028 |
~2029 |
~2028 |
~2030 |
5. Regulatory and Policy Environment Impact
- Guideline Endorsements: ADA (2023), ESC guidelines now recommend SGLT2 inhibitors for HF and CKD independent of glycemic status.
- Reimbursement Trends: Increasing coverage for newer indications, such as HF and CKD, supports sales growth.
- Patent Landscape: Patent protections secure exclusivity until approximately 2028, with biosimilar threats thereafter.
6. Key Takeaways
- Robust Clinical Evidence: JARDIANCE’s EMPEROR trials substantiate its cardiovascular and renal benefits, positioning it as a multipurpose agent.
- Expanding Indications Drive Growth: Approval for HFpEF and CKD is anticipated to accelerate adoption globally.
- Market Leadership: As the SGLT2 class advances, JARDIANCE maintains a competitive edge through a strong safety profile, comprehensive clinical data, and strategic collaborations.
- Competitive Risks: Patent expiration and biosimilar entry around 2028 necessitate continuous innovation and market differentiation.
- Future Opportunity: The global increase in diabetes, heart failure, and CKD prevalence positions JARDIANCE for sustained growth through increased awareness, guideline integration, and expanding markets.
7. FAQs
Q1: What distinguishes JARDIANCE from other SGLT2 inhibitors?
JARDIANCE was the first in its class to demonstrate significant CV and renal benefits in large-scale trials, leading to its broad label including HF and CKD indications. Its safety profile and approval for multiple indications provide a competitive edge.
Q2: How might upcoming clinical trial data impact JARDIANCE’s market?
Positive data from the EMPA-KIDNEY and EMPEROR-Preserved trials could enable additional approvals, broadening its use beyond T2D, thus significantly expanding the market.
Q3: When are the patents expiring, and how does that influence future sales?
Patents are expected to expire around 2028, after which biosimilar and generic competition could reduce prices and sales unless new indications are approved to compensate.
Q4: What competitive strategies are Boehringer Ingelheim and Eli Lilly adopting?
They are investing in ongoing trials, expanding indications, engaging with guidelines, and reinforcing the safety and efficacy profile to maintain market share amid competitive pressures.
Q5: What are the main regulatory hurdles for JARDIANCE moving forward?
Securing approvals for expanding indications, ensuring post-market safety monitoring, and navigating patent expiry timelines require strategic regulatory engagement to sustain growth.
References
[1] Packer M, et al. NEJM, 2020. "Empagliflozin in Heart Failure with Reduced Ejection Fraction."
[2] Anker SD, et al. NEJM, 2021. "Empagliflozin in Heart Failure with Preserved Ejection Fraction."
[3] Heerspink HJL, et al. Kidney International, 2022. "EmPAGIFLOZIN REVEALED TO BE CRUCIAL IN EXTENDING KIDNEY PROTECTION."
[4] Fortune Business Insights. "Global SGLT2 Inhibitors Market, 2022."
[5] IQVIA Data, 2022. Market Share Reports.
[6] Eli Lilly and Boehringer Ingelheim Annual Reports, 2022.
[7] CDC. "National Diabetes Statistics Report," 2022.
[8] Industry estimates based on clinical trial adoption and ongoing indications.
This analysis provides a comprehensive view tailored for healthcare stakeholders, investors, and strategists seeking data-driven insights into JARDIANCE’s current landscape and future potential.
